Myopia progression after cessation of <scp>low‐dose</scp> atropine eyedrops treatment: A <scp>two‐year</scp> randomized, <scp>double‐masked</scp>, <scp>placebo‐controlled</scp>, <scp>cross‐over</scp> trial

Abstract

The difference in myopia progression between atropine-placebo group and placebo-atropine group in Phase 1 was similar to Phase 2 during the cross-over treatment. Through our cross-over trial, the results suggest that there is no rebound effect after using 0.01% atropine eye drops to prevent progression of myopia.